BBS Faculty Member - Benjamin Ebert

Benjamin Ebert

Department of Medicine

Brigham and Women's Hospital
Karp Building, CHRB 5.210
75 Francis Street
Boston, MA 02115
Tel: 617-355-9091
Fax: 617-355-9124
Visit my lab page here.

The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies, with a particular focus on myelodysplastic syndromes (MDS). In large-scale genetic analyses of patient samples, the lab has identified somatic mutations that predict prognosis and response to therapies in MDS patients, characterized a pre-malignant state of hematopoietic cells, and derived the molecular ontogeny of genetic lesions in myeloid malignancies. In addition to human genetic studies, the lab has elucidated the biological basis of transformation of hematopoietic cells by these somatic mutations and developed novel in vivo models to study myeloid malignancies. The lab employs genetic and small molecule screens to identify novel therapeutic targets and small molecules for the treatment of hematologic malignancies and sickle cell disease.

The Ebert lab elucidated the mechanism of action of lenalidomide, a derivative of thalidomide. Lenalidomide and related drugs modulate the function of an E3 ubiquitin ligase, inducing drug-dependent degradation of specific substrates that are essential for the survival of multiple myeloma and MDS cells, representing the first drugs that bind and modulate the function of an E3 ubiquitin ligase.

Last Update: 8/6/2015


For a complete listing of publications click here.



Kronke J, Udeshi ND, Narla A, Grauman, P, Hurst SN, McConkey M, Svinka T, Heckl D, Comer E, Li X, Ciarlo C, Hartman E, Munshi N, Schenone M, Schreiber SL, Carr SA, Ebert BL. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science, 2014, 343:301-5.

Schneider RK, Adema V, Heckl D, Jaras M, Mallo M, Lord MA, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Sole F,
Ebert BL. Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell, 2014, 26:509-20.

Jaiswal S., Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A, Higgins, JM Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI on behalf of T2D-GENES, Boehnke M on behalf of GoT2D, Altshuler D on behalf of SIGMA T2D, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, Neuberg D, Altshuler D,
Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine 2014, 371(26):2488-98.

Kronke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, Chamberlain PP, Mani DR, Man HW, Gandhi AK, Svinkina T, Schneider RK, McConkey M, Jaeras M, Griffiths E, Wetzler M, Bullinger L, Cathers BE, Carr SA, Chopra R,
Ebert BL. Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS. Nature, 2015, 523: 183-8.

© 2015 by the President and Fellows of Harvard College